Jake Simson - 11 Jun 2026 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Reporting relationship: Director
Issuer ticker: JANX
Reported as of: 11 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jun 2026, 20:00:15 UTC
Prior SEC filing: 09 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ James Pennington, Attorney-in-Fact

Key filing fact

Jake Simson filed Form 4 for Janux Therapeutics, Inc. (JANX) on 12 Jun 2026.

Key facts

This page summarizes Jake Simson's Form 4 filing for Janux Therapeutics, Inc. (JANX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 12 Jun 2026, 20:00.

Change

Previous filing in this sequence was filed on 09 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001863094 Primary reporting owner

Simson Jake

Relationship: Director
Address: C/O JANUX THERAPEUTICS, INC., 10955 VISTA SORRENTO PARKWAY, SUITE 200, SAN DIEGO
Signature: /s/ James Pennington, Attorney-in-Fact
Signature date: 12 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

JANX transaction

Common Stock

Award

Transaction value
Shares: +5,500
Change %: +88%
Price: $0.000000^*
Shares after: 11,750
Date: 11 Jun 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

JANX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +15,500
Change %
Price: $0.000000^*
Shares after: 15,500
Date: 11 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,500
Exercise price: $13.66
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.

Footnote F2

Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Advisor"), the Reporting Person holds the option and RSUs reported for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and the RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The Reporting Person is obligated to turn over to the Advisor any net cash or stock received upon exercise of the option or settlement of the RSUs, as applicable, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Advisor. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock.

Footnote F3

The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.